Drug products: Altargo®
ATC code: D06AX13
The efficacy of retapamulin in treatment of skin infections is similar in men and women. However, studies of dosing and adverse events with a relevant gender analysis are scarce.
In our opinion, the present evidence does not motivate differentiation in dosing or treatment between men and women.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of retapamulin have been found.
The efficacy of topical retapamulin in patients with secondarily infected traumatic lesions was evaluated in a randomized, double-blind, placebo-controlled study (219 men, 140 women; all ages >2 months). Men/boys and women/girls receiving retapamulin had similar success rates, measured as clinical improvement . Also, the original manufacturer report similar responses to retapamulin in treatment of impetigo in both sexes in clinical studies [2, 3].
Clinical trials of retapamulin safety have not reported sex-stratified results [1, 4].
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2016-03-29
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson